A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression

J Thorac Oncol. 2018 Jul;13(7):e120-e122. doi: 10.1016/j.jtho.2018.03.004.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / deficiency*
  • DNA Damage
  • DNA Mismatch Repair*
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Prognosis

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • durvalumab